Khanna; Richie

Patent Applications and Registrations

Patent applications and USPTO patent grants for Khanna; Richie.The latest application filed is for "recombinant human acid alpha-glucosidase".

Company Profile

4.12.13

Khanna; Richie - Somerset NJ
Khanna; Richie - Piscataway NJ

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Augmented acid alpha-glucosidase for the treatment of Pompe disease Grant 11,278,601 - Do , et al. March 22, 2	2022-03-22
High concentration alpha-glucosidase compositions for the treatment of Pompe disease Grant 11,278,599 - Valenzano , et al. March 22, 2	2022-03-22
Recombinant Human Acid Alpha-glucosidase App 20210393747 - DO; Hung ; et al.	2021-12-23
Augmented Acid Alpha-glucosidase For The Treatment Of Pompe Disease App 20210268074 - DO; Hung V. ; et al.	2021-09-02
Augmented acid alpha-glucosidase for the treatment of Pompe disease Grant 10,857,212 - Do , et al. December 8, 2	2020-12-08
High Concentration Alpha-glucosidase Compositions For The Treatment Of Pompe Disease App 20200188494 - Valenzano; Kenneth ; et al.	2020-06-18
High concentration alpha-glucosidase compositions for the treatment of pompe disease Grant 10,512,677 - Valenzano , et al. Dec	2019-12-24
.alpha.-galactosidase A and 1-deoxygalactonojirimycin co-formulation Grant 10,357,548 - Khanna , et al. July 23, 2	2019-07-23
High Concentration Alpha-glucosidase Compositions For The Treatment Of Pompe Disease App 20180360928 - Valenzano; Kenneth ; et al.	2018-12-20
Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease Grant 10,155,027 - Khanna , et al. Dec	2018-12-18
Augmented Acid Alpha-glucosidase For The Treatment Of Pompe Disease App 20180228877 - Do; Hung V. ; et al.	2018-08-16
High concentration alpha-glucosidase compositions for the treatment of Pompe disease Grant 10,046,033 - Valenzano , et al. August 14, 2	2018-08-14
Alpha-Galactosidase A And 1-Deoxygalactonojirimycin Co-Formulation App 20170360901 - Khanna; Richie ; et al.	2017-12-21
Alpha-Galactosidase A And 1-Deoxygalactonojirimycin Co-Formulation For The Treatment of Fabry Disease App 20170209548 - Khanna; Richie ; et al.	2017-07-27
Augmented Acid Alpha-Glucosidase For The Treatment Of Pompe Disease App 20170189497 - Do; Hung V. ; et al.	2017-07-06
.alpha.-galactosidase A and 1-deoxygalactonojirimycin co-formulation Grant 9,694,056 - Khanna , et al. July 4, 2	2017-07-04
High Concentration Alpha-Glucosidase Compositions For The Treatment Of Pompe Disease App 20170056483 - Valenzano; Kenneth ; et al.	2017-03-02
High concentration alpha-glucosidase compositions for the treatment of Pompe disease Grant 9,404,100 - Valenzano , et al. August 2, 2	2016-08-02
High concentration .alpha.-glucosidase compositions for the treatment of Pompe disease Grant 9,303,249 - Valenzano , et al. April 5, 2	2016-04-05
Alpha-galactosidase A And 1-deoxygalactonojirimycin Co-formulation App 20150174214 - Khanna; Richie ; et al.	2015-06-25
High Concentration Alpha-Glucosidase Compositions for the Treatment of Pompe Disease App 20150044194 - Valenzano; Kenneth Joseph ; et al.	2015-02-12
High Concentration Alpha-Glucosidase Compositions for the Treatment of Pompe Disease App 20140193390 - Valenzano; Kenneth ; et al.	2014-07-10
Mouse model for pompe disease and methods of use thereof Grant 8,466,340 - Khanna , et al. June 18, 2	2013-06-18
Mouse Model For Pompe Disease And Methods Of Use Thereof App 20120064545 - Khanna; Richie ; et al.	2012-03-15

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.